Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.

International journal of antimicrobial agents - 1 Aug 2020

André-Garnier Elisabeth, Hingrat Quentin Le, Marcelin Anne-Geneviève, Reliquet Véronique, Malet Isabelle, Leducq Valentin, Rodallec Audrey, Peytavin Gilles, Ferré Virginie, Charpentier Charlotte, Raffi François

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Emtricitabine
Share to Heterocyclic Compounds, 3-Ring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterocyclic Compounds, 4 or More Rings

Share to HIV Integrase

Share to HIV Integrase Inhibitors

Share to Pyridones

Share to Tenofovir

Source

Identifiers

PMID: 32479891
DOI: 10.1016/j.ijantimicag.2020.106039

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.PMID 32479891Read ↗

Resistance to Integrase InhibitorsSemantic proximity Read ↗

Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug ResistanceSemantic proximity Read ↗

Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.Semantic proximity Read ↗

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profilesSemantic proximity Read ↗

HIV-1 Integrase Variants Retarget Viral Integration and Are Associated with Disease Progression in a Chronic Infection CohortSemantic proximity Read ↗

Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literatureSemantic proximity Read ↗

Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.Semantic proximity Read ↗

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.Semantic proximity Read ↗

The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.Semantic proximity Read ↗

Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.Semantic proximity Read ↗

Antiviral activity of HIV‐1 integrase strand‐transfer inhibitors against mutants with integrase resistance‐associated mutations and their frequency in treatment‐naïve individualsSemantic proximity Read ↗

The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.